Abstract
Background: Mendelian randomisation (MR) studies show that higher body mass index (BMI) and lower 25-hydroxyvitamin D (25[OH]D) increase psoriasis risk. The combined effect of these factors has not been explored using factorial MR. Methods: Using cross-sectional data from UK Biobank (UKB, n=398 404) and the Troendelag Health Study (HUNT, n=86 648), we calculated polygenic risk scores for BMI and 25(OH)D to estimate odds ratios for psoriasis using 2x2 and continuous factorial MR. We quantified additive interaction by relative excess risk due to interaction (RERI)-estimates. We also performed traditional observational analyses in UKB. Results: There were 12 207 (3.1%) participants with psoriasis in UKB and 7794 (9.0%) in HUNT. In 2x2 factorial MR, we found no evidence of relative excess risk for psoriasis due to interaction between genetically predicted higher BMI and lower 25(OH)D, neither in UKB (RERI -0.01, 95% confidence interval (CI) -0.08, 0.07) nor in HUNT (RERI -0.04, 95% CI -0.14, 0.06). The same was observed in the continuous factorial MR and observational analyses. Conclusions: This study did not find evidence of interaction between BMI and 25(OH)D on the risk of psoriasis. Given minor differences in measured BMI and 25(OH)D between groups, small effects may have been undetected.
Competing Interest Statement
Conflict of interest declaration: Kjersti Danielsen reports to have served as a consultant, lecturer or participated in sponsored events/meetings by Novartis, Abbvie, LEO Pharma, UCB Pharma, Almirall, Meda Pharma, Bristol Myers Squibb, Galderma and Celgene. Other authors: None declared.
Funding Statement
Funding sources that supported the work: Marita Jenssen, Kjersti Danielsen and Anne-Sofie Furberg have received research grants from Northern Norway Regional Health Authority (grant number HNF1361-17 (MJ) and SFP1167-14 (KD, ASF), the Odd Berg Medical Research Foundation (MJ, KD) and the Norwegian Society of Dermatology and Venereology (MJ). Mari Loeset and Ben Brumpton are supported by grants from the Liaison Committee for Education, Research and Innovation in Central Norway and the Joint Research Committee between St Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNU. Yi-Qian Sun was supported by a Researcher grant from the Liaison Committee for Education, Research, and Innovation in Central Norway (project ID 2018/42794). The other authors state no funding supporting the work reported in the manuscript. The funders were not involved in the design and conduct of the study; nor in the collection, management, analysis, and interpretation of the data; nor in the preparation, review, or approval of the manuscript; nor in the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants have provided written informed consent. The National Health Service National Research Ethics Service approved the UKB (reference 11/NW/0382). The Regional Committee for Medical and Health Research Ethics (REK) Central approved the HUNT Study. The present study was conducted using the UKB Resource under application number 40135, and was approved by the REK, Mid-Norway (2015/2003).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data may be obtained from a third party and are not publicly available. The UKB resource is available to bona fide researchers for health-related research in the public interest (https://www.ukbiobank.ac.uk/enable-your-research). Access to data from the HUNT Study can be given to researchers with a PhD associated with Norwegian research institutes upon application to HUNT's Data Access Committee, given approval by a Regional Committee for Medical and Health Research Ethics. Researchers outside of Norway are welcome to apply for the use of HUNT data in cooperation with a Norwegian Principal Investigator (https://www.ntnu.edu/hunt/data).